Similar articles

• Gonadotropin-releasing hormone agonists for the management of ovarian cysts in menopause breast cancer patients on tamoxifen treatment.

  Kourounis G, Zervoudis S, Michail G, Fotopoulos A. Kourounis G, et al. Breast J. 2005 Sep-Oct;11(5):365-6. doi: 10.1111/j.1075-122X.2005.21715.x. Breast J. 2005. PMID: 16174165 Clinical Trial. No abstract available.
• Risk of menopause during the first year after breast cancer diagnosis.

  Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Goodwin PJ, et al. J Clin Oncol. 1999 Aug;17(8):2365-70. doi: 10.1200/JCO.1999.17.8.2365. J Clin Oncol. 1999. PMID: 10561298
• Symptoms associated with tamoxifen treatment in postmenopausal women.

  Love RR, Cameron L, Connell BL, Leventhal H. Love RR, et al. Arch Intern Med. 1991 Sep;151(9):1842-7. Arch Intern Med. 1991. PMID: 1888251 Clinical Trial.
• Adjuvant chemotherapy for breast cancer. NIH consensus development conference, September 9-11, 1985.

  [No authors listed] [No authors listed] Cancer Treat Res. 1992;60:375-82. Cancer Treat Res. 1992. PMID: 1355999 Review. No abstract available.
• [Tamoxifen in breast cancer: viewpoint of the gynecologist].

  De Muylder X. De Muylder X. Acta Clin Belg. 1992;47(3):178-84. Acta Clin Belg. 1992. PMID: 1332348 Review. French.